


Read & Publish Open Access initiative



Disease Models & Mechanisms



Launched in 2008, Disease Models & Mechanisms is an Open Access biomedical research journal that advances understanding of the mechanism, diagnosis and therapy of human disease.



Interdisciplinary in scope, Disease Models & Mechanisms covers a diverse range of diseases, including cancer, infectious diseases, developmental disorders, musculoskeletal disorders, and neurodegenerative and neurological diseases. Published research utilizes *in vitro* or *ex vivo* models, such as stem-cell-based models, organoids, patient material, model organisms, microorganisms, viruses and computational approaches.

In addition to Research and Resources & Methods articles, Disease Models & Mechanisms features expert reviews, perspectives and interviews with leading scientists to address current and emerging themes in biomedical science.

Readership

Disease Models & Mechanisms aspires to connect and support all those working at every level of disease research, from basic researchers to clinicians at the forefront of patient care. Content is freely available to the journal's communities of basic and clinical researchers, those working for pharmaceutical companies, health professionals, patients and their advocates and families.

Abstracting and indexing services

Disease Models & Mechanisms is abstracted and/or indexed by (amongst others): BIOBASE, CAB abstracts, Cambridge Scientific Abstracts, Current Contents, EMBASE, Clarivate Analytics Web of Science, Medline, Scopus and the Directory of Open Access Journals (DOAJ).

Open Access commitment

The journal is 100% Open Access, making your research easily and immediately available to everyone to read and share. Our fully Open Access journals are included in the majority of our Read & Publish agreements.

Key metrics

- 2024 Impact Factor: 3.3
- Five-year Impact Factor: 3.9
- Article citation median: 2
- Eigenfactor score: 0.00703
- Article Influence Score: 1.243
- Cited half-life: 7.5
- Immediacy Index: 1.0
- h-index: 113
- Scopus CiteScore: 6.5
- SJR indicator: 1.318
- SNIP: 0.865





Expert team of academic editors

Editor-in-Chief

- E. Elizabeth Patton (MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, UK)

Deputy Editor-in-Chief

- Elaine R. Mardis (Nationwide Children's Hospital, Ohio, USA)

Editors

- James Amatruda (Children's Hospital Los Angeles, CA, USA)
- Steven J. Clapcote (University of Leeds, UK)
- Vivian Li (The Francis Crick Institute, London, UK)
- Karen Liu (King's College London, UK)
- Satdarshan (Paul) Singh Monga (University of Pittsburgh, PA, USA)
- Owen Sansom (Beatson Institute for Cancer Research, Glasgow, UK)
- David M. Tobin (Duke University School of Medicine, Durham, NC, USA)
- Shinya Yamamoto (Baylor College of Medicine, USA)

Associate Editors

- Sally Dunwoodie (Victor Chang Cardiac Research Institute, Australia)
- Monkol Lek (Yale School of Medicine, USA)
- Ian Smyth (Monash University, Australia)
- Eckhard Wolf (Gene Center, LMU Munich, Germany)

What are the benefits of Read & Publish agreements?

- Uncapped fee-free Open Access publishing of research articles in all our journals: Development, Journal of Cell Science, Journal of Experimental Biology, Disease Models & Mechanisms and Biology Open
- Unlimited "read" access to our three transformative journals (Development, Journal of Cell Science and Journal of Experimental Biology) and their archives
- Transparent cost-neutral pricing
- Reduces admin – single annual fee covers reading and publishing
- Easy to switch from a subscription to a Read & Publish agreement
- Easy compliance with funders' Open Access mandates



“ I was delighted to discover that Disease Models & Mechanisms is part of a Read & Publish agreement with the Centro Nacional de Investigaciones Cardiovasculares (CNIC). This arrangement not only streamlined the publishing process but also made it free of charge for authors, ensuring that top-tier research can be published in leading journals without financial barriers. I hope more publishers will follow the forward-thinking example set by The Company of Biologists.”

José Luis De La Pompa, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain

Benefits of Open Access publishing



Usage increase **>3x**




Citation advantage **1.1-1.4x**



Altmetrics boost **1.2-1.9x**

Read & Publish: number of participating institutions



Figures based on data from Impact Vizor and Altmetric Explorer

